

Scot Garg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6659534/publications.pdf>

Version: 2024-02-01

149
papers

10,310
citations

76196

40
h-index

33814

99
g-index

156
all docs

156
docs citations

156
times ranked

7751
citing authors

#	ARTICLE	IF	CITATIONS
1	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. EuroIntervention, 2023, 19, e807-e831.	1.4	5
2	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 28-38.	1.4	39
3	Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease. European Heart Journal, 2022, 43, 1334-1344.	1.0	17
4	10-Year All-Cause Mortality Following Percutaneous or Surgical Revascularization in Patients With Heavy Calcification. JACC: Cardiovascular Interventions, 2022, 15, 193-204.	1.1	23
5	Sex-specific difference of in-hospital mortality from COVID-19 in South Korea. PLoS ONE, 2022, 17, e0262861.	1.1	8
6	Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. American Heart Journal, 2022, 246, 32-43.	1.2	1
7	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	1.6	4
8	Clinical Outcomes of Drug-Coated Balloon Treatment After Successful Revascularization of de novo Chronic Total Occlusions. Frontiers in Cardiovascular Medicine, 2022, 9, 821380.	1.1	9
9	Quantitative Angiographic Assessment of Aortic Regurgitation Following 11 TAVR Devices: An Update of a Multicenter Pooled Analysis. , 2022, , 100037.		5
10	Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial. EuroIntervention, 2022, 18, 492-502.	1.4	8
11	Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. EuroIntervention, 2022, 18, e377-e388.	1.4	16
12	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2022, 100, 72-82.	0.7	4
13	Letter by Kawashima et al Regarding Article, "Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion and Multivessel Disease": Circulation: Cardiovascular Interventions, 2022, 15, e012080.	1.4	0
14	Predicted and Observed Mortality at 10 Years in Patients With Bifurcation Lesions in the SYNTAX Trial. JACC: Cardiovascular Interventions, 2022, 15, 1231-1242.	1.1	16
15	Are We Unisex When Undergoing Left Main Revascularization?. , 2022, , 100345.		0
16	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. Journal of the American College of Cardiology, 2022, 80, 63-88.	1.2	25
17	Periprocedural Outcomes Associated With Use of a Left Atrial Appendage Occlusion Device in China. JAMA Network Open, 2022, 5, e2214594.	2.8	14
18	Mortality after multivessel revascularisation involving the proximal left anterior descending artery. Heart, 2022, 108, 1784-1791.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial. Canadian Journal of Cardiology, 2021, 37, 122-130.	0.8	4
20	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. International Journal of Cardiology, 2021, 324, 30-37.	0.8	4
21	Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A) Tj ETQq1 1 0.784314 rgBT /@verlock	1.4	10
22	A Clinical Risk Score to Predict In-hospital Mortality from COVID-19 in South Korea. Journal of Korean Medical Science, 2021, 36, e108.	1.1	5
23	Drug-coated balloon treatment for nonsmall de-novo coronary artery disease: angiographic and clinical outcomes. Coronary Artery Disease, 2021, 32, 534-540.	0.3	4
24	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. JACC: Cardiovascular Interventions, 2021, 14, 444-456.	1.1	27
25	Predicting 2-yr all-cause mortality after contemporary <scp>PCI</scp>: Updating the logistic clinical <scp>SYNTAX</scp> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	0.7	6
26	Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006581.	0.9	10
27	Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 547-556.	1.4	3
28	34-yr...Next generation P2Y12 inhibitors improve survival in ACS: an analysis from the british cardiovascular intervention society database. , 2021, , .		0
29	10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease. Journal of the American College of Cardiology, 2021, 77, 2761-2773.	1.2	32
30	Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 2021, 78, 384-407.	1.2	16
31	Provisional drug-coated balloon treatment guided by physiology on de novo coronary lesion. Cardiology Journal, 2021, 28, 615-622.	0.5	6
32	Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data?. European Heart Journal, 2021, 42, 2665-2669.	1.0	5
33	Coronary Computed Tomographic Angiography for Complete Assessment of Coronary Artery Disease. Journal of the American College of Cardiology, 2021, 78, 713-736.	1.2	66
34	Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease. Clinical Research in Cardiology, 2021, 110, 1680-1691.	1.5	4
35	Have We Overdefined Periprocedural Myocardial Infarction to the Point of Extinction?. JACC: Cardiovascular Interventions, 2021, 14, 1635-1638.	1.1	7
36	Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. European Heart Journal, 2021, 43, 56-67.	1.0	23

#	ARTICLE	IF	CITATIONS
37	Ten-year all-cause mortality following staged percutaneous revascularization in patients with complex coronary artery disease. <i>Cardiovascular Revascularization Medicine</i> , 2021, , .	0.3	0
38	External Validation of the SYNTAX Score II 2020. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1227-1238.	1.2	30
39	A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Angio-iFR (ReVEAL iFR) study. <i>American Heart Journal</i> , 2021, 239, 19-26.	1.2	4
40	A Case of Aneurysm Occurring at the Dissection Site after Intervention with Drug-Coated Balloon. <i>Korean Circulation Journal</i> , 2021, 51, 376.	0.7	0
41	Sex-Related Outcomes of Successful Drug-Coated Balloon Treatment in De Novo Coronary Artery Disease. <i>Yonsei Medical Journal</i> , 2021, 62, 981.	0.9	2
42	Comparison of Clinically Adjudicated Versus Flow-Based Adjudication of Revascularization Events in Randomized Controlled Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008055.	0.9	4
43	Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 100-111.	0.7	16
44	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 21.	3.0	49
45	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. <i>Canadian Journal of Cardiology</i> , 2020, 36, 747-755.	0.8	2
46	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1369-1378.	0.7	6
47	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 918-929.	1.5	3
48	Sex Differences in All-Cause Mortality in the Decade Following Complex Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 76, 889-899.	1.2	30
49	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 179.	2.7	14
50	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2020, 320, 27-34.	0.8	4
51	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009177.	1.4	15
52	Impact of Peri-Procedural Myocardial Infarction on Outcomes After Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1622-1639.	1.2	73
53	Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1087-1095.	1.8	14
54	Effect of Sex Difference of Coronary Microvascular Dysfunction on Long-Term Outcomes in Deferred Lesions. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1669-1679.	1.1	20

#	ARTICLE	IF	CITATIONS
55	DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 634-646.	1.1	17
56	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. <i>Atherosclerosis</i> , 2020, 295, 45-53.	0.4	36
57	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 930-943.	1.5	14
58	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E516-E526.	0.7	5
59	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1125-1139.	1.5	14
60	Impact of Dissection after Drug-Coated Balloon Treatment of De Novo Coronary Lesions: Angiographic and Clinical Outcomes. <i>Yonsei Medical Journal</i> , 2020, 61, 1004.	0.9	8
61	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2223-2234.	1.2	101
62	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2015-2027.	1.2	23
63	Plaque modification and stabilization after paclitaxel-coated balloon treatment for de novo coronary lesions. <i>Heart and Vessels</i> , 2019, 34, 1113-1121.	0.5	12
64	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). <i>BMJ Open</i> , 2019, 9, e026053.	0.8	18
65	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. <i>International Journal of Cardiology</i> , 2019, 286, 43-50.	0.8	19
66	Prospective evaluation of an ultrathin strut biodegradable polymer-coated sirolimus-eluting stent: 12 months'™ results from the S-FLEX UK registry. <i>BMJ Open</i> , 2019, 9, e026578.	0.8	7
67	Prospective randomized trial of paclitaxel-coated balloon versus bare-metal stent in high bleeding risk patients with de novo coronary artery lesions. <i>Coronary Artery Disease</i> , 2019, 30, 425-431.	0.3	14
68	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e539-e546.	1.4	16
69	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e1090-e1098.	1.4	16
70	Impact of paclitaxel-coated balloon versus newer-generation drug-eluting stent on periprocedural myocardial infarction in stable angina patients. <i>Coronary Artery Disease</i> , 2018, 29, 403-408.	0.3	2
71	Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study. <i>Scientific Reports</i> , 2018, 8, 1229.	1.6	26
72	Paclitaxel-coated balloon treatment for functionally nonsignificant residual coronary lesions after balloon angioplasty. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 1339-1347.	0.7	15

#	ARTICLE	IF	CITATIONS
73	Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. <i>European Heart Journal</i> , 2018, 39, 3381-3389.	1.0	29
74	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet</i> , The, 2018, 392, 940-949.	6.3	555
75	The contribution of gender and age on early and late mortality following ST-segment elevation myocardial infarction: results from the Korean Acute Myocardial Infarction National Registry with Registries. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 205-214.	0.2	5
76	Association of Inter-Arm Systolic Blood Pressure Difference with Coronary Atherosclerotic Disease Burden Using Calcium Scoring. <i>Yonsei Medical Journal</i> , 2017, 58, 954.	0.9	6
77	A Comparison of Peri-Procedural Myocardial Infarction between Paclitaxel-Coated Balloon and Drug-Eluting Stent on De Novo Coronary Lesions. <i>Yonsei Medical Journal</i> , 2017, 58, 99.	0.9	5
78	Comparison of Paclitaxel-Coated Balloon Treatment and Plain Old Balloon Angioplasty for De Novo Coronary Lesions. <i>Yonsei Medical Journal</i> , 2016, 57, 337.	0.9	23
79	Serial Morphological Changes of Side-Branch Ostium after Paclitaxel-Coated Balloon Treatment of De Novo Coronary Lesions of Main Vessels. <i>Yonsei Medical Journal</i> , 2016, 57, 606.	0.9	25
80	Letter by Garg et al Regarding Article, "Percutaneous Coronary Intervention at Centers With and Without On-Site Surgical Backup: An Updated Meta-Analysis of 23 Studies" <i>Circulation</i> , 2016, 133, e406.	1.6	0
81	First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, E248-60.	0.7	44
82	Gender differences in risk factors and clinical outcomes in young patients with acute myocardial infarction. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 1057-1064.	2.0	15
83	Gender differences in plaque characteristics of culprit lesions in patients with ST elevation myocardial infarction. <i>Heart and Vessels</i> , 2016, 31, 1767-1775.	0.5	12
84	Outcomes of Percutaneous Coronary Intervention Performed at Offsite Versus Onsite Surgical Centers in the United Kingdom. <i>Journal of the American College of Cardiology</i> , 2015, 66, 363-372.	1.2	22
85	Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5433 patients enrolled in contemporary coronary stent trials. <i>International Journal of Cardiology</i> , 2015, 187, 111-115.	0.8	26
86	Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: An analysis of the SYNTAX Study. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 199-206.	0.7	32
87	Reproducibility of coronary artery calcium measurements using 0.8-mm-thickness 256-slice coronary CT. <i>Japanese Journal of Radiology</i> , 2014, 32, 677-684.	1.0	5
88	Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. <i>Heart</i> , 2014, 100, 1158-1164.	1.2	216
89	Remote ischemic preconditioning in hemodialysis: a pilot study. <i>Heart and Vessels</i> , 2014, 29, 58-64.	0.5	14
90	An Update on Drug-Eluting Stents. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 61-78.	0.4	4

#	ARTICLE	IF	CITATIONS
91	New concepts in the design of drug-eluting coronary stents. <i>Nature Reviews Cardiology</i> , 2013, 10, 248-260.	6.1	107
92	Seizure-associated takotsubo cardiomyopathy presenting with unheralded ventricular fibrillation. <i>International Journal of Cardiology</i> , 2012, 162, e21-e23.	0.8	24
93	Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 467-478.	0.7	47
94	Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 695-703.	0.7	21
95	Left Radial versus Right Radial Approach for Coronary Artery Catheterization: A Prospective Comparison. <i>Journal of Interventional Cardiology</i> , 2012, 25, 203-209.	0.5	37
96	Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 51-58.	0.7	19
97	Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: The MI SYNTAXscore study. <i>American Heart Journal</i> , 2011, 161, 771-781.	1.2	106
98	Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents. <i>American Heart Journal</i> , 2011, 162, 1069-1079.e2.	1.2	16
99	Impact of Body Mass Index on the Five-Year Outcome of Patients Having Percutaneous Coronary Interventions With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2011, 108, 195-201.	0.7	37
100	Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 859-866.	0.7	21
101	5-Year Follow-Up of Coronary Revascularization in Diabetic Patients With Multivessel Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 317-323.	1.1	58
102	Focus on the research utility of intravascular ultrasound - comparison with other invasive modalities. <i>Cardiovascular Ultrasound</i> , 2011, 9, 2.	0.5	15
103	Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with <i>de novo</i> coronary artery lesions: The SPIRIT II trial. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 1012-1017.	0.7	28
104	Prediction of 1-Year Clinical Outcomes Using the SYNTAX Score in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 66-75.	1.1	132
105	The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 432-441.	1.1	98
106	A Patient-Level Pooled Analysis Assessing the Impact of the SYNTAX (Synergy Between Percutaneous) Tj ETQq0 0 0 rgBT /Overlock 10 T Patients Enrolled in Contemporary Coronary Stent Trials. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 645-653.	1.1	70
107	Revascularization treatment of stable coronary artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 195-212.	0.9	15
108	Relationship between right ventricular volumes measured by cardiac magnetic resonance imaging and prognosis in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 52-60.	2.9	76

#	ARTICLE	IF	CITATIONS
109	Value of Age, Creatinine, and Ejection Fraction (ACEF Score) in Assessing Risk in Patients Undergoing Percutaneous Coronary Interventions in the "All-Comers" LEADERS Trial. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 47-56.	1.4	109
110	A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. <i>European Heart Journal</i> , 2011, 32, 294-304.	1.0	58
111	SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of Sirolimus-eluting stent compared with paclitaxel-eluting stent for coronary revascularization (SIRTAX) trial. <i>European Heart Journal</i> , 2011, 32, 3115-3127.	1.0	136
112	The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. <i>EuroIntervention</i> , 2011, 6, 928-935.	1.4	19
113	Five-year outcomes of percutaneous coronary intervention compared to bypass surgery in patients with multivessel disease involving the proximal left anterior descending artery: an ARTS-II sub-study. <i>EuroIntervention</i> , 2011, 6, 1060-1067.	1.4	10
114	Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the "Call-comers" LEADERS trial. <i>EuroIntervention</i> , 2011, 7, 605-613.	1.4	21
115	The Impact of Body Mass Index on the One Year Outcomes of Patients Treated by Percutaneous Coronary Intervention With Biolimus- and Sirolimus-Eluting Stents (from the LEADERS Trial). <i>American Journal of Cardiology</i> , 2010, 105, 475-479.	0.7	49
116	Impact of Completeness of Revascularization on the Five-Year Outcome in Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Patients (from the ARTS-II Study). <i>American Journal of Cardiology</i> , 2010, 106, 1369-1375.	0.7	76
117	IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 914-918.	0.7	18
118	The SYNTAX score revisited: A reassessment of the SYNTAX score reproducibility. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 946-952.	0.7	69
119	Bifurcation lesions: Functional assessment by fractional flow reserve vs. anatomical assessment using conventional and dedicated bifurcation quantitative coronary angiogram. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 817-823.	0.7	17
120	Long-Term Clinical Results Following Stenting of the Left Main Stem. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 584-594.	1.1	49
121	Clinical and Angiographic Risk Assessment in Patients With Left Main Stem Lesions. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 891-901.	1.1	29
122	A Comparison of the Conformability of Everolimus-Eluting Bioresorbable Vascular Scaffolds to Metal Platform Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1190-1198.	1.1	92
123	Clinical Indications for Intravascular Ultrasound Imaging. <i>Echocardiography</i> , 2010, 27, 1282-1290.	0.3	14
124	A New Tool for the Risk Stratification of Patients With Complex Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 317-326.	1.4	236
125	In Vivo 3D Distribution of Lipid-Core Plaque in Human Coronary Artery as Assessed by Fusion of Near Infrared Spectroscopy "Intravascular Ultrasound and Multislice Computed Tomography Scan. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, e6-7.	1.3	29
126	Takotsubo Cardiomyopathy: A Review of the Literature. <i>Angiology</i> , 2010, 61, 166-173.	0.8	41

#	ARTICLE	IF	CITATIONS
127	Endothelial progenitor cell capture stents: will this technology find its niche in contemporary practice?. <i>European Heart Journal</i> , 2010, 31, 1032-1035.	1.0	30
128	Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 38, S1-S52.	0.6	405
129	Benefits of and safety concerns associated with drug-eluting coronary stents. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 449-470.	0.6	24
130	Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2010, 56, S43-S78.	1.2	278
131	First-in-Man Clinical Use of Combined Near-Infrared Spectroscopy and Intravascular Ultrasound. <i>Journal of the American College of Cardiology</i> , 2010, 56, 314.	1.2	59
132	5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1093-1101.	1.2	218
133	Value of the SYNTAX Score for Risk Assessment in the All-Comers Population of the Randomized Multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) Trial. <i>Journal of the American College of Cardiology</i> , 2010, 56, 272-277.	1.2	198
134	Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2010, 56, S1-S42.	1.2	447
135	Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1357-1365.	1.2	363
136	Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. <i>New England Journal of Medicine</i> , 2010, 363, 136-146.	13.9	608
137	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	1.0	2,649
138	First use in patients of a combined near infra-red spectroscopy and intra-vascular ultrasound catheter to identify composition and structure of coronary plaque. <i>EuroIntervention</i> , 2010, 5, 755-756.	1.4	52
139	In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. <i>EuroIntervention</i> , 2010, 5, 932-938.	1.4	73
140	A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. <i>EuroIntervention</i> , 2010, 6, 195-205.	1.4	41
141	The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. <i>EuroIntervention</i> , 2010, 6, 233-239.	1.4	49
142	Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: Insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (Research) Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 979-986.	0.7	28
143	3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1190-1198.	1.1	89
144	Coronary angioplasty: do we need to EuroSCORE?. <i>Nature Reviews Cardiology</i> , 2009, 6, 267-268.	6.1	5

#	ARTICLE	IF	CITATIONS
145	Assessment of the SYNTAX score in the Syntax study. EuroIntervention, 2009, 5, 50-56.	1.4	480
146	Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientific work of Dr. Hideo Tamai. EuroIntervention, 2009, 5, F109-F111.	1.4	27
147	How should I treat a complex Post-CABG patient?. EuroIntervention, 2009, 5, 627-632.	1.4	0
148	Research Utility of Intravascular Ultrasound. Advances in Bioinformatics and Biomedical Engineering Book Series, 0, , 109-136.	0.2	0
149	Analysis of the Existing Data Fusion Methodologies for 3D Coronary Imaging. Advances in Bioinformatics and Biomedical Engineering Book Series, 0, , 278-291.	0.2	0